Page results
-
This page has been written for patients who wish to find out more about a new procedure for epilepsy that does not involve removing parts of brain, known as EASEE® (Epicranial Application of Stimulation Electrodes for Epilepsy)
-
This leaflet explains the support a transition coordinator at the Adolescent Rheumatology Department provides, and how they can help.
-
Information for patients and visitors on patient isolation.
-
This information is for patients, (and their family and carers), who are considering having Uterine Artery (Fibroid) Embolisation (UAE). It explains what is involved and the possible risks.
-
It is important to make sure you are eating and drinking well before your surgery. Good nutrition will also help you recover after your surgery.
-
This page has been written for patients who are having a course of superficial radiotherapy for a skin tumour (such as a basal cell carcinoma or squamous cell carcinoma), or some other skin condition.
-
This page is for patients who are having stereotactic ablative body radiotherapy (SABR) for lung cancer.
-
This information has been written to help you now that your radiotherapy treatment is finishing.
-
This page has been written for parents and carers whose child is having radiotherapy treatment to the neck, chest, abdomen, and pelvis.
-
This page is for parents and carers whose child is having radiotherapy treatment to the neck and chest.
File results
-
FOI/2022/0276 - Biologic medicines within dermatology
-
FOI/2022/0278 - Surgical tables in use at Trust
-
FOI/2022/0280 - Applications or tools to communicate digitally with patients
-
FOI/2022/0282 - Decontamination and infection control leads; risk assessment group meetings
-
FOI/2022/0283 - Enhanced disinfection methods to eliminate HAIs in theatres, clinical areas and wards
-
FOI/2022/0285 - Paediatric audiology
-
FOI/2022/0286 - Fat-shaming complaints
-
FOI/2022/0287 - Device related delays in delivery of medication/ enteral feeding
-
FOI/2022/0288 - Patient deaths awaiting discharge as inpatient
-
FOI/2022/0293 - Patients treated with Ponvory, Tysabri, Vumerity, Zeposia